https://assets.capyfin.com/instruments/678fdc13234e27009c5d6386.png avatar
PMV Pharma
🇺🇸 NASDAQ:PMVP
View Company
OverviewEarningsDividends
•
Dec 31, 2023

PMV Pharma Q4 2023 Earnings Report

PMV Pharmaceuticals reported its financial results for Q4 and full year 2023, highlighting the progress of rezatapopt and an extended cash runway.

Key Takeaways

PMV Pharmaceuticals reported its full year 2023 financial results, with a focus on the advancement of rezatapopt and the extension of the company's cash runway to the end of 2026 through cost savings initiatives. The registrational Phase 2 clinical trial for rezatapopt remains on track to initiate in Q1 2024.

Registrational Phase 2 clinical trial of rezatapopt remains on track to initiate in Q1 2024.

Phase 1 analysis of rezatapopt in ovarian cancer patients selected for presentation at the 2024 SGO Annual Meeting.

Updated Phase 1 data demonstrated responses across multiple tumor types with a 38% overall response rate.

Cash, cash equivalents, and marketable securities totaled $228.6 million as of December 31, 2023, with runway extended to the end of 2026.

Total Revenue
$0
EPS
-$0.31
Previous year: -$0.43
-27.9%
Gross Profit
-$359K
Cash and Equivalents
$37.7M
Previous year: $108M
-65.2%
Free Cash Flow
-$12.3M
Previous year: -$17M
-27.6%
Total Assets
$252M
Previous year: $270M
-6.7%

PMV Pharma

PMV Pharma

Forward Guidance

PMV Pharma is focused on advancing the rezatapopt clinical program and has extended its cash runway to the end of 2026.

Positive Outlook

  • Registrational, tumor-agnostic Phase 2 portion of PYNNACLE clinical trial of rezatapopt remains on track to initiate in Q1 2024
  • Phase 1 analysis from the PYNNACLE Phase 1/2 study of rezatapopt in a subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation selected as a late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer
  • Cost savings from January 2024 workforce reduction expected to extend cash runway to end of 2026
  • Alignment with FDA on RP2D and key elements of single arm, tumor agnostic Phase 2 registrational portion of PYNNACLE study
  • Initiated enrollment in the combination arm of the PYNNACLE study with rezatapopt and KEYTRUDA® (pembrolizumab).

Challenges Ahead

  • The company is still operating at a loss
  • Workforce reduction to extend cash runway
  • Clinical trials are subject to risks and uncertainties
  • The company's ability to fund operations
  • Impact that any current or future global pandemic or geopolitical emergency may have on the Company’s clinical trials, supply chain, and operations

Company Overview

Full financial data and analysis

View PMV Pharma